JP2012522529A5 - - Google Patents

Download PDF

Info

Publication number
JP2012522529A5
JP2012522529A5 JP2012503990A JP2012503990A JP2012522529A5 JP 2012522529 A5 JP2012522529 A5 JP 2012522529A5 JP 2012503990 A JP2012503990 A JP 2012503990A JP 2012503990 A JP2012503990 A JP 2012503990A JP 2012522529 A5 JP2012522529 A5 JP 2012522529A5
Authority
JP
Japan
Prior art keywords
fviii molecule
fviii
antibody
molecule
gpiib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012503990A
Other languages
English (en)
Japanese (ja)
Other versions
JP5770161B2 (ja
JP2012522529A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2010/054495 external-priority patent/WO2010115866A1/en
Publication of JP2012522529A publication Critical patent/JP2012522529A/ja
Publication of JP2012522529A5 publication Critical patent/JP2012522529A5/ja
Application granted granted Critical
Publication of JP5770161B2 publication Critical patent/JP5770161B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012503990A 2009-04-06 2010-04-06 血小板への第ｖｉｉｉ因子タンパク質の標的送達 Expired - Fee Related JP5770161B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21200409P 2009-04-06 2009-04-06
US61/212,004 2009-04-06
US18607509P 2009-06-11 2009-06-11
US61/186,075 2009-06-11
PCT/EP2010/054495 WO2010115866A1 (en) 2009-04-06 2010-04-06 Targeted delivery of factor viii proteins to platelets

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015125394A Division JP2015166391A (ja) 2009-04-06 2015-06-23 血小板への第ｖｉｉｉ因子タンパク質の標的送達

Publications (3)

Publication Number Publication Date
JP2012522529A JP2012522529A (ja) 2012-09-27
JP2012522529A5 true JP2012522529A5 (OSRAM) 2013-04-25
JP5770161B2 JP5770161B2 (ja) 2015-08-26

Family

ID=42238764

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012503990A Expired - Fee Related JP5770161B2 (ja) 2009-04-06 2010-04-06 血小板への第ｖｉｉｉ因子タンパク質の標的送達
JP2015125394A Pending JP2015166391A (ja) 2009-04-06 2015-06-23 血小板への第ｖｉｉｉ因子タンパク質の標的送達

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015125394A Pending JP2015166391A (ja) 2009-04-06 2015-06-23 血小板への第ｖｉｉｉ因子タンパク質の標的送達

Country Status (6)

Country Link
US (2) US20120093840A1 (OSRAM)
EP (1) EP2417155B1 (OSRAM)
JP (2) JP5770161B2 (OSRAM)
CN (1) CN102482340B (OSRAM)
ES (1) ES2427627T3 (OSRAM)
WO (1) WO2010115866A1 (OSRAM)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
WO2009108806A1 (en) * 2008-02-27 2009-09-03 Novo Nordisk A/S Conjugated factor viii molecules
JP5997443B2 (ja) * 2008-05-16 2016-09-28 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 標的化凝固因子およびそれを使用する方法
CN102482340B (zh) * 2009-04-06 2015-05-13 诺沃—诺迪斯克有限公司 因子viii蛋白向血小板的靶向递送
ES2541369T3 (es) * 2010-02-16 2015-07-17 Novo Nordisk A/S Factor VIII recombinante modificado
JP5914363B2 (ja) * 2010-02-16 2016-05-11 ノヴォ ノルディスク アー／エス 低減されたｖｗｆ結合を有する因子ｖｉｉｉ分子
DK2591006T3 (da) 2010-07-09 2019-07-29 Bioverativ Therapeutics Inc Processerbare enkeltkædede molekyler og polypeptider fremstillet ved anvendelse deraf
RU2013142015A (ru) * 2011-03-02 2015-04-10 Ново Нордиск А/С Нацеливание факторов свертывания крови на рецептор tlt-1 на поверхности активированных тромбоцитов
CA2875247A1 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Chimeric clotting factors
AU2013270682A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Procoagulant compounds
WO2014041500A2 (en) * 2012-09-12 2014-03-20 Centre For Bioseparation Technology-Vit Double mutant coagulation factor viii and methods thereof
CN104661685A (zh) 2012-10-15 2015-05-27 诺和诺德保健Ag（股份有限公司） 因子vii缀合物
EP2914293A4 (en) 2012-10-30 2016-04-20 Biogen Ma Inc METHOD OF USE OF FVIII POLYPEPTIDE
ES2959747T3 (es) 2013-02-15 2024-02-28 Bioverativ Therapeutics Inc Gen del factor VIII optimizado
PL3666283T3 (pl) * 2013-03-15 2022-10-03 Bioverativ Therapeutics Inc. Formulacje polipeptydu czynnika viii
UY35463A (es) 2013-03-15 2014-10-31 Biogen Idec Inc Formulaciones de polipéptido fc-factor ix.
US10364288B2 (en) 2013-05-24 2019-07-30 Biogen Ma Inc. Anti-GPIIB/IIIA antibodies or uses thereof
MX2016004702A (es) 2013-10-15 2016-07-22 Novo Nordisk Healthcare Ag Polipeptidos del factor vii de coagulacion.
US10325687B2 (en) 2013-12-06 2019-06-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
US10822393B2 (en) 2014-01-20 2020-11-03 Octapharma Ag Process for manufacturing factor VIII having an improved ratio of FVIII:C/FVIII/AG
WO2016004113A1 (en) 2014-06-30 2016-01-07 Biogen Ma Inc. Optimized factor ix gene
ES2788870T3 (es) 2014-08-04 2020-10-23 Csl Ltd Formulación de factor VIII
MA40835A (fr) 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
DK3265483T3 (da) 2015-03-06 2020-03-02 CSL Behring Lengnau AG Modificeret von Willebrand-faktor med forbedret halveringstid
CN108603877A (zh) * 2015-10-02 2018-09-28 Tgr生物科学私人有限公司 使用多基质的分析物检测
US10189888B2 (en) 2015-11-13 2019-01-29 Baxalta Incorporated Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A
EP3411478B1 (en) 2016-02-01 2022-06-08 Bioverativ Therapeutics Inc. Optimized factor viii genes
EP3205665A1 (en) * 2016-02-11 2017-08-16 Octapharma AG Method of separating factor viii from blood products
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
CA3106590A1 (en) 2018-07-16 2020-01-23 Baxalta Incorporated Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
TWI851647B (zh) 2019-01-16 2024-08-11 日商武田藥品工業股份有限公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
CN114072420B (zh) 2019-07-04 2024-06-11 康诺贝林伦瑙有限公司 用于增加凝血因子viii的体外稳定性的截短的血管性血友病因子(vwf)
US12403164B2 (en) 2019-09-30 2025-09-02 Bioverativ Therapeutics Inc. Lentiviral vector formulations
US20220348637A1 (en) 2019-11-11 2022-11-03 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii
JP2023537565A (ja) 2020-06-24 2023-09-04 バイオベラティブ セラピューティクス インコーポレイテッド タンパク質を発現するように改変されたレンチウイルスベクターの調製物から遊離第ｖｉｉｉ因子を除去する方法
CN113248594B (zh) * 2021-04-26 2022-08-30 北京美康基免生物科技有限公司 一种重组凝血因子viii及其应用
EP4662240A2 (fr) 2023-02-09 2025-12-17 Commissariat à l'Energie Atomique et aux Energies Alternatives Fragment fab mutant pour l'obtention de conjugués mono- ou bi-fonctionnalisés site-spécifiques

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2645588A (en) 1987-12-04 1989-06-15 Scripps Clinic And Research Foundation The von willebrand factor binding domain of factor viii
KR940009084B1 (ko) * 1988-05-18 1994-09-29 체크 포인트 시스템스, 인코오퍼레이티드 자기 및 공명회로 검출용 안테나 시스템
JPH0433A (ja) 1990-04-11 1992-01-06 Nissan Motor Co Ltd 粘度可変流体封入制御型エンジンマウント
JPH0434A (ja) 1990-04-13 1992-01-06 Tokai Rubber Ind Ltd 流体封入式筒型マウント装置
US5629384A (en) 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
JP4361133B2 (ja) * 1994-07-11 2009-11-11 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム 血管系の特異的凝固のための方法および組成物
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
GB9724143D0 (en) * 1997-11-14 1998-01-14 Andaris Ltd Pharmaceutical conjugate
US20030236190A1 (en) 1998-09-02 2003-12-25 Renuka Pillutla Isulin and IGF-1 receptor agonists and antagonists
CA2462930C (en) 2001-10-10 2012-07-10 Shawn De Frees Remodeling and glycoconjugation of peptides
JP2008507990A (ja) 2004-08-02 2008-03-21 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｆｖｉｉの抱合体
EP1778839B1 (en) 2004-08-13 2008-07-09 Roche Diagniostics GMBH C-terminal modification of polypeptides
EP1871801A2 (en) * 2005-04-01 2008-01-02 Novo Nordisk Health Care AG Blood coagulation fviii analogues
JP5570809B2 (ja) * 2006-09-01 2014-08-13 ノボ ノルディスク ヘルス ケア アーゲー 修飾タンパク質
JP5448839B2 (ja) * 2006-12-22 2014-03-19 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー インビボで長い半減期を有する修飾された凝固因子
WO2009108806A1 (en) * 2008-02-27 2009-09-03 Novo Nordisk A/S Conjugated factor viii molecules
JP5997443B2 (ja) 2008-05-16 2016-09-28 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 標的化凝固因子およびそれを使用する方法
CN102482340B (zh) * 2009-04-06 2015-05-13 诺沃—诺迪斯克有限公司 因子viii蛋白向血小板的靶向递送

Similar Documents

Publication Publication Date Title
JP2012522529A5 (OSRAM)
Yeboah et al. Elastin‐like polypeptides: A strategic fusion partner for biologics
Przybyla et al. Metal-triggered radial self-assembly of collagen peptide fibers
EP3372617A3 (en) Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
EP4450523A3 (en) Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
NZ602943A (en) Modified binding proteins inhibiting the vegf-a receptor interaction
WO2013040093A3 (en) Glucagon-like peptide-2 compositions and methods of making and using same
JP2016000731A5 (OSRAM)
JP2019526248A5 (OSRAM)
JP2018522563A5 (OSRAM)
NZ600278A (en) Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto
JP2010534486A5 (OSRAM)
BR112012007294A2 (pt) moléculas de ligação a dll4
JP2014504150A5 (OSRAM)
JP2015519313A5 (OSRAM)
PE20080694A1 (es) Anticuerpo de c-kit humanizado
WO2007123765A3 (en) Neutrokine-alpha and neutrokine-alpha splice variant
WO2008114149A3 (en) Respiratory syncytial virus (rsv) chimeric polypeptide comprising the g protein central region domain located in between the f2 and f1 fusion protein domains
MY188897A (en) Factor viii compositions and methods of making and using same
HRP20221447T1 (hr) Fuzijski proteini koji sadrže dijelove za vezanje pdgf i vegf i postupci njihove upotrebe
ATE533782T1 (de) Impfstoffe und immuntherapeutika mit codon- optimiertem il-15 und verwendungsverfahren dafür
JP2015501656A5 (OSRAM)
BR112014022166A2 (pt) gene da delta-endotoxina axmi345 e métodos para a sua utilização
WO2011146891A3 (en) High-affinity fully functional soluble single-domain human cd4, antibodies, and related fusion proteins
EP4368194A3 (en) Thrombin cleavable linker with xten and its uses thereof